What is the current status of the inclisiran patent?
Inclisiran is a cholesterol-lowering medication developed by Novartis. The medication uses a novel approach to target and degrade PCSK9, a protein that helps regulate cholesterol levels. According to DrugPatentWatch.com [1], the patents covering inclisiran are expected to expire in 2037-2038, depending on the country and region.
Why are companies challenging this patent?
There are ongoing patent disputes surrounding inclisiran. Novartis has been sued by several companies, including Alnylam Pharmaceuticals, which claims that inclisiran infringes on its own RNAi-related patents [2]. The validity and enforceability of these patents will be determined in court. If the patent is invalidated or narrowed, it could allow other companies to develop similar cholesterol-lowering medications without infringing on Novartis' intellectual property.
How does this drug compare with Keytruda?
While inclisiran and Keytruda are both medications, they operate in different therapeutic areas and use distinct mechanisms to address specific medical needs. Keytruda is an immunotherapy used to treat various types of cancer, whereas inclisiran targets high cholesterol. There is no direct comparison between the two medications, as they have different indications, formulations, and modes of administration.
What side effects are patients asking about?
As with any medication, inclisiran carries potential side effects [3]. Common adverse reactions include injectionsite reactions, headache, nausea, fatigue, and muscle pain. Novartis has released data showing that inclisiran was well-tolerated in clinical trials, but it is essential for patients to discuss any concerns with their healthcare provider.
Can biosimilars enter before patent expiry?
The entry of biosimilars will depend on several factors, including patent status, regulatory clearance, and market demand. If Novartis' patent is invalidated or expires, biosimilars might be able to enter the market. However, the introduction of biosimilars is subject to a complex interplay of regulatory, patent, and business considerations.
Sources:
[1] DrugPatentWatch.com - Inclisiran patent information
[2] Alnylam Pharmaceuticals - Lawsuit against Novartis regarding inclisiran patent
[3] Novartis - Inclisiran clinical trial data